Nieland; John

Patent Applications and Registrations

Patent applications and USPTO patent grants for Nieland; John.The latest application filed is for "mutated parvovirus structural proteins as vaccines".

Company Profile

3.7.16

Nieland; John - Aarhus-C DK
NIELAND; John - Aarhus DK
Nieland; John - Arhus C DK
Nieland; John - Munich DE
Nieland; John - Stockdorf DE
Nieland; John - Munchen DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Mutated structural protein of a parvovirus Grant 10,822,378 - Lux , et al. November 3, 2	2020-11-03
Mutated Parvovirus Structural Proteins As Vaccines App 20200191788 - BUENING; Hildegard ; et al.	2020-06-18
Mutated parvovirus structural proteins as vaccines Grant 10,408,834 - Buening , et al. Sept	2019-09-10
Mutated Structural Protein Of A Parvovirus App 20180066024 - LUX; Kerstin ; et al.	2018-03-08
Mutated structural protein of a parvovirus Grant 9,624,274 - Lux , et al. April 18, 2	2017-04-18
Mutated Parvovirus Structural Proteins As Vaccines App 20160153992 - BUENING; Hildegard ; et al.	2016-06-02
Mutated Parvovirus Structural Proteins As Vaccines App 20130288921 - BUENING; Hildegard ; et al.	2013-10-31
Mutated Structural Protein Of A Parvovirus App 20130108658 - LUX; Kerstin ; et al.	2013-05-02
Mutated Parvovirus Structural Proteins As Vaccines App 20100297177 - Buening; Hildegard ; et al.	2010-11-25
Mutated Structural Protein Of A Parvovirus App 20100203083 - Lux; Kerstin ; et al.	2010-08-12
Tetranectin Trimerizing Polypeptides App 20100028995 - Graversen; Jonas Heilskov ; et al.	2010-02-04
Trimeric IL-1Ra App 20090143276 - Holtet; Thor Las ; et al.	2009-06-04
Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases Grant 7,528,168 - Nieland , et al. May 5, 2	2009-05-05
Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases App 20060089406 - Nieland; John ; et al.	2006-04-27
Cytotoxic T-cell epitopes of the papillomavirus L1-protein and use thereof in diagnostics and therapy Grant 6,911,207 - Jochmus , et al. June 28, 2	2005-06-28
Cellular vaccines comprising adjuvants App 20050085433 - Breidenstein, Claudia ; et al.	2005-04-21
Allogenic vaccine that contains a costimulatory polypeptide-expresing tumor cell App 20050025789 - Nieland, John ; et al.	2005-02-03
Topical use of cytokines and chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases App 20050008614 - Nieland, John ; et al.	2005-01-13
Cytotoxic T-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy Grant 6,838,084 - Jochmus , et al. January 4, 2	2005-01-04
Cytotoxic T-cell epitopes of papillomavirus L1 protein and their use in diagnostics and therapy App 20040258708 - Jochmus, Ingrid ; et al.	2004-12-23
Medicament for preventing or treating tumors caused by human papilloma virus type 18 App 20040101533 - Muller, Rainer ; et al.	2004-05-27
T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy App 20040091479 - Nieland, John ; et al.	2004-05-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.